Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
      QxMD      Google Scholar   
Citation:
Clin. Cancer Res. vol 23 (22) 6802-6811
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
DataSharing:
No
Book Volume:
6
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA032291, U10CA077651, U10CA007968, U10CA180791, U10CA180867, 5UO1CA157703, 3U10CA180821-03S3, PC121341, U01 CA157703, U10 CA077202, U10 CA031946, U10 CA180821, U10 CA180863  
Corr. Author:
 
Authors:
                                   
Primary Study
CALGB-90203
Secondary Studies:
Phases:
3
Keywords:
high-risk prostate cancer, neoadjuvant, docetaxel, ADT, genomics, integrative molecular analysis